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Summary
 
Dendritic cells (DCs) are known to activate naive T cells to become effective helper cells. In
addition, recent evidence suggests that DCs may influence naive B cells during the initial prim-
 
ing of antibody responses. In this study, using three-color confocal microscopy and three-
dimensional immunohistograms, we have observed that in the first few days after a primary im-
munization, cells with dendritic morphology progressively localize within primary B cell
follicles. These cells were identified by their ability to bind a fusion protein consisting of the
terminal cysteine-rich portion of the mouse mannose receptor and the Fc portion of human
immunoglobulin (Ig)G1 (CR-Fc). In situ, these CR-Fc binding cells express major histocom-
patibility complex class II, sialoadhesin, and CD11c and are negative for other markers identi-
fying the myeloid DC lineage, such as (CD11b), macrophages (F4/80), follicular DCs (FDC-
M2), B cells (B220), and T cells (CD4). Using CR-Fc binding capacity and flow cytometry,
the cells were purified from the draining lymph nodes of mice 24 h after immunization. When
injected into naive mice, these cells were able to prime T cells as well as induce production of
antigen-specific IgM and IgG1. Furthermore, they produced significantly more of the lympho-
cyte chemoattractant, macrophage inflammatory protein (MIP)-1
 
a
 
, than isolated interdigitat-
ing cells. Taken together, these results provide evidence that a subset of DCs enters primary
follicles, armed with the capacity to attract and provide antigenic stimulation for T and B lym-
phocytes.
Key words: dendritic cells • mannose receptor • antibody production • antigen presentation • 
chemokines
 
A
 
ntigen-specific lymphocytes, to initiate T cell–depen-
dent antibody responses, must extravasate from the
circulation into secondary lymphoid tissues, where they
encounter signals for activation. Maturing dendritic cells
(DCs)
 
1
 
 migrate via blood or lymph into these organs and
efficiently prime naive T cells (1, 2). This process involves
the presentation of not only peptides but also costimulatory
signals such as CD80 and CD86, the production of cyto-
kines such as IL-12, and the release of chemokines such as
IL-8, macrophage inflammatory protein (MIP)-1
 
a
 
, and
MIP-1
 
b 
 
(3–5).
Although much is known concerning DC–T cell inter-
actions, it is only recently that investigators have found ev-
idence that DCs may directly influence the production of
antibody. Highly purified human CD1a
 
1
 
 DCs have been
shown to stimulate activated B cells to produce IgM and
IgG in vitro (6). Furthermore, Wykes and colleagues have
shown that rat DCs can transfer antigen to B cells and ini-
tiate a primary antibody response in vivo (7). Hence, it ap-
pears that DCs may have a broader role in lymphocyte acti-
vation than previously appreciated.
Studies performed by Kelsoe and colleagues originally
suggested that early B cell activation occurs in the outer T
cell zones of splenic periarteriolar sheaths (8–10). These
foci were visualized due to the antigen-binding capacity of
the B cells and, with time, contained an increased number
of antigen-specific plasma cells. However, a recently pub-
lished study using an adoptive transfer system of transgenic
B and T cells has shown that early cognate interactions lo-
 
1
 
Abbreviations used in this paper:
 
 BM-DC, bone marrow–derived DC; CR,
cysteine-rich; 3D, three-dimension; DC, dendritic cell; FDC, follicular
DC; MFI, mean fluorescence intensity; MIP, macrophage inflammatory
protein; RANTES, regulated upon activation, normal T cell expressed
and secreted. 
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calize to the follicular border in lymph nodes (11). The
height of this interaction occurred at day 2–4 after immu-
nization, suggesting that lymph node T and B cell priming
events occur in these areas.
Previously in our laboratory, a chimeric protein was
generated as a means to determine which cell types express
ligands for the cysteine-rich (CR) domain of the murine
mannose receptor (12). This chimera consisted of the CR
domain of the mannose receptor fused to the Fc region of
human IgG1 (CR-Fc). In conjunction with immunohis-
tochemistry, the CR-Fc fusion protein revealed that cells
with dendritic morphology accumulated in primary B cell
follicles during the initial phases of an immune response
while interdigitating cells in the paracortex remained nega-
tive (12). This observation was intriguing, leading us to de-
velop methods to characterize this population in situ and ex
vivo. The results reported here demonstrate that CR-Fc
binding provides a marker for isolating a novel murine sub-
set of CD11c
 
1
 
 DCs that localize to B cell follicles and ini-
tiate humoral responses.
 
Materials and Methods
 
Animals and Immunizations.
 
Female Balb/c mice were pur-
chased from Janvier and kept under pathogen-free conditions.
They were used at 8–12 wk of age. Mice were primed subcuta-
neously in each limb (50 
 
m
 
g) and in the back of the neck (100 
 
m
 
g)
with chicken egg OVA (Sigma Chemical Co.) precipitated in
alum (13).
 
Cryosections.
 
Lymph nodes were obtained on days 0–4 after
the primary immunization with OVA. Organs of a particular day
were collected together and frozen in OCT compound on dry
ice. The blocks were then cut into 10-
 
m
 
m-thick sections, air
dried for 1 h, acetone fixed for 10 min, and finally stored at
 
2
 
20
 
8
 
C.
 
Generation of the CR-Fc Fusion Protein.
 
The CR-Fc fusion pro-
tein was generated as described elsewhere (12). In brief, the CR
domain of the mannose receptor was amplified by reverse tran-
scription PCR and cloned into the pIG expression vector. The
resulting plasmid was transfected into Cos-7 cells. The chimeric
protein consisting of CR fused to the Fc portion of human IgG1
was purified from supernatants of transfected cells by protein A
chromatography and stored at 
 
2
 
20
 
8
 
C.
 
Immunohistochemistry.
 
To characterize in situ the population
binding the CR-Fc fusion protein, triple-color confocal micros-
copy was used. For this, CR-Fc binding cells were identified
with Cy5 (
 
l
 
em
 
 5 
 
670 nm), IgM
 
1
 
 B cells with Texas red (
 
l
 
em
 
 5
 
615 nm), and a third protein with FITC (
 
l
 
em
 
 5 
 
525 nm). These
were excited with the 633- and 543-nm HeNe lasers and a 488-nm
argon laser, respectively. This triple labeling then offered the
most efficient strategy to (a) locate CR-Fc binding cells (blue) in
relation to the IgM
 
1
 
 B cell follicles (red); and then (b) determine
if the blue cells expressed either a specific molecule or were adja-
cent to a certain cell type (green). The antibodies used for this
third variable parameter included the following: N418 (anti-CD11c),
M1/70 (anti-CD11b), 53-6.7 (anti-CD8
 
a
 
), T24 (anti-CD90/
anti–Thy 1), GK 1.5 (anti-CD4), 14.8 (anti-B220), Syndecan-1
(anti-CD138), Ser-4/3D6 (antisialoadhesin), biotinylated FDC-M2
(anti-FDC), F4/80 (antimacrophage), biotinylated 14.4.4 (anti–
MHC class II), and biotinylated NLDC-145 (anti-DEC205; a
 
generous gift of K. Shortman, The Walter and Eliza Hall Institute
of Medical Research, Melbourne, Australia). These mAbs, with
the exception of NLDC-145, were either obtained from Ameri-
can Tissue Culture Collection and produced in house or, when
available, purchased from PharMingen. Secondary antibodies and
reagents included Texas red–conjugated rat anti–mouse IgM
(Southern Biotechnology Associates), Cy5-conjugated mouse
anti–human IgG (Jackson ImmunoResearch Laboratories), strep-
tavidin-Cy5 (Caltag Laboratories), FITC-conjugated mouse
anti–rat IgG (Southern Biotechnology Associates), FITC-con-
jugated mouse anti–rat IgG, FITC-conjugated mouse anti–
human IgG (both from Jackson ImmunoResearch Laborato-
ries), and FITC-conjugated goat anti–hamster IgG (Southern
Biotechnology Associates). Human IgG (Jackson Immuno-
Research Laboratories) was used as a control for nonspecific
binding of CR-Fc.
 
Three-dimension Immunohistograms.
 
The photomicrographs
were computer analyzed using a program developed in house.
The program divides the image into 4,096 squares (64 
 
3
 
 64).
The mean fluorescence intensity (MFI) is calculated for each of
the squares and stored in a matrix. The MFI is then represented as
a three-dimension (3D) histogram (
 
x
 
, 
 
y
 
 
 
5 
 
position of the square,
 
z
 
 
 
5 
 
MFI). The 3D immunohistograms can represent single pa-
rameters as well as an overlay of two or more colors.
 
Isolation of CR-Fc Binding Cells.
 
Mice were injected with
OVA precipitated in alum (50 
 
m
 
g s.c. per limb and 100 
 
m
 
g s.c.
behind the neck). 24 h later, the draining lymph nodes were col-
lected and the cells recovered using an enzyme cocktail contain-
ing collagenase and DNAse (14). The low buoyant density cells
(
 
d
 
 
 
5 
 
1.057–1.065 g/ml) were collected from Percoll gradients,
and B cells were depleted with anti-B220–coated Dynabeads
(Dynal). The remaining cells were sequentially incubated with
CR-Fc (10 
 
m
 
g/ml) and N418 (10 
 
m
 
g/ml), biotinylated mouse
anti–human IgG (1:100) and goat anti–hamster FITC (1:100;
Southern Biotechnology Associates), and Streptavidin-PE (1:100;
Serotec) before separation by flow cytometry. All washes and di-
lutions of reagents for FACS
 
®
 
 used a solution consisting of PBS
containing 10% FCS.
 
T Lymphocyte Priming In Vivo.
 
For assessing in vivo T cell
priming, the N418
 
1
 
/CR-Fc
 
 
 
binding cells were injected subcuta-
neously into the right side of naive mice. 7 d later, the draining
(right side) and nondraining (left side) lymph nodes were col-
lected separately, and the cells were recovered using the enzyme
cocktail. The cells (obtained from the nondraining versus drain-
ing lymph nodes) were then fractionated using discontinuous
Percoll gradients (15). The T cell band (
 
d
 
 
 
5 
 
1.081–1.085 g/ml)
was collected and incubated with a cocktail of anti-CD8 (54.6.7),
anti–MHC class II (14.4.4), and anti-B220 (14.8) coated Dy-
nabeads according to the manufacturer’s specifications. This
method produced 
 
.
 
98% CD4
 
1
 
 T cells. The T cells (2 
 
3
 
 10
 
5
 
cells/well) were then incubated for 48 h in medium (IMDM, 5%
FCS, 
 
l
 
-glutamine, penicillin/streptomycin, and 2-ME) with
spleen cells (irradiated with 30 Gy; 2 
 
3
 
 10
 
5
 
 cells/well) in the
presence or absence of 10 
 
m
 
g/ml OVA. For the final 24 h of cul-
ture, [
 
3
 
H]thymidine was added and incorporation measured using
a 
 
b
 
-counter (Wallac).
 
T Lymphocyte Priming In Vitro.
 
N418
 
1
 
/CR-Fc
 
 
 
binding cells
were isolated as specified above and cultured overnight with T
cells isolated from DO11.10 mice (i.e., transgenic for an OVA-
specific T cell receptor [16]).
 
 
 
At 24 h, [
 
3
 
H]thymidine was added,
and incorporation was measured 24 h later.
 
B Lymphocyte Priming In Vivo.
 
For assessing in vivo B cell
activation, both the N418
 
1
 
/CR-Fc
 
 
 
binding fraction and the 
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Figure 1. Localization of CR-Fc binding cells in lymph nodes with time after a primary immunization. Three-color confocal analysis was used in or-
der to determine when and where CR-Fc binding cells appeared in the tissue. Cryostat sections prepared from murine lymph nodes obtained at days
0–4 (A–E) of a primary response were processed for IgM expression (red), N418 labeling (green), and CR-Fc binding (blue). The images were then digi-
tally transformed using a computer program in order to map the MFI (in arbitrary units) for either single (CR-Fc1; N4181) or double (CR-Fc1/ N4181)
positive cells. The resulting 3D immunohistograms revealed that CR-Fc binding cells accumulated with time in the outer part of the B cell follicles.
Many of these cells were also N4181 (see the CR-Fc1/N4181 column). The scale 0–250 represents the MFI, with the colors yellow, blue, green, and
red representing values in the 100–150, 150–200, 200–250, and .250 range, respectively. 
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Table I.
 
Profile of CR-Fc
 
1
 
 Cells in B Cell Follicles on Days 0, 1, 
2, 3, and 4 of a Primary Immune Response
 
Marker (mAb)
CD11c (N418)
 
1
 
MHC class II (14.4.4)
 
1
 
Sialoadhesin (Ser-4/3D6)
 
1
 
F4/80 (F4/80)
 
2
 
CD11b (M1/70)
 
2
 
CD8
 
a
 
 (53-6.7)
 
2
 
/
 
1
 
*
 
Dec 205 (NLDC-145)
 
2
 
FDC-M2 (209)
 
2
 
CD90 (T24)
 
2
 
/
 
1
 
*
 
CD4 (GK 1.5)
 
2
 
B220 (14.8)
 
2
 
CD138 (Syndecan-1)
 
2
 
/
 
1
 
*
*
 
A minor subset of cells was identified as positive on days 3 and 4.
N418
 
1
 
/CR-Fc
 
 
 
nonbinding population (representing interdigi-
tating cells) were isolated as specified above. The CR-Fc binding
cells were injected subcutaneously into the right forelimb while
the CR-Fc nonbinding cells were injected subcutaneously into
the left forelimb of naive mice. 7 d later, three sets of lymph
nodes were collected and processed separately: (1) the draining
lymph nodes receiving CR-Fc
 
1
 
 cells (i.e., right axial and bra-
chial), (2) the draining (i.e., left axial and brachial) lymph nodes
receiving CR-Fc nonbinding cells, and (3) the lymph nodes re-
ceiving no cells (inguinal and paraaortic). Cells were recovered
using the enzyme cocktail and fractionated using discontinuous
Percoll gradients (15). The low buoyant density band (
 
d
 
 
 
5
 
1.060–1.065 g/ml) was obtained and cultured for 1 h at 37
 
8
 
C to
remove adherent cells. The nonadherent cells were then incu-
bated (3 
 
3
 
 10
 
5
 
 cells/well) in 96-well plates containing medium.
After 7 d, the supernatants were collected, and OVA-specific an-
tibody titers were assessed using standard ELISA procedures.
 
FACS
 
®
 
 Analysis.
 
The hybridomas 2.4G2 (anti-CD32) and
YN1.1.7 (anti-CD54) were obtained from American Type Cul-
ture Collection, 7G6 (anti-CD21/35) from Dr. T. Kinoshita
(Osaka University, Osaka, Japan), FGK (anti-CD40) from Dr. A.
Rolink (Basel Institute for Immunology, Basel, Switzerland), and
B3B4 (anti-CD23) from Dr. D. Conrad (Virginia Common-
wealth University, Richmond, VA). 1G10 (anti-CD80), GL1
(anti-CD86), and 145-2c11 (anti-CD3) were purchased from
PharMingen. The hybridoma Ser-4/3D6 (anti–mouse siaload-
hesin) was generated in our laboratory. The secondary reagent
was the mouse anti–rat IgG (H
 
1
 
L) F(ab
 
9
 
)
 
2
 
 fragments conjugated
to FITC (Jackson Immunoresearch Laboratories), and the control
antibody, rat IgG, was purchased from Sigma Chemical Co.
 
Chemokine Production.
 
N418
 
1
 
/CR-Fc  binding and N4181/
CR-Fc nonbinding cells were purified using flow cytometry ac-
cording to the protocol mentioned above. In addition, DCs were
derived from mouse bone marrow according to the protocol by
Metlay et al. (17). In brief, the bone marrow was flushed from
femurs, pipetted into a single cell suspension, and then incubated
at 378C, 5% CO2 for 2 d in the presence of GM-CSF. At days 2
and 3, the nonadherent cells were removed after gentle pipetting,
discarded, and new medium containing GM-CSF was added to
the remaining adherent cells. On day 6, the nonadherent cells
were harvested and shown to contain $99% N4181 cells by flow
cytometry. Cells were incubated at 378C in 96-well plates (2 3
105 cells/well) in 200 ml IMDM plus 5% FCS (GIBCO BRL).
Supernatants were harvested at 24 h, and chemokine levels were
determined by ELISA using mouse-RANTES (kit MMR00;
R&D Systems) and mouse–MIP-1a (kit MMA00; R&D Sys-
tems) kits according to the manufacturer’s specifications.
Results
Determining the Phenotype In Situ of CR-Fc Binding Cells.
During an immune response, it has been previously shown
that within lymph nodes, cells with dendritic morphology
bind the CR-Fc fusion protein (12). To further investigate
their nature, we developed a system involving immuno-
histochemistry and three-color microscopy. As shown in
Fig. 1, the B cell follicles were visualized using an anti-IgM
antibody conjugated to Texas red. CR-Fc binding cells
were labeled with Cy5-conjugated reagents. A third
marker associated with FITC was then used to determine
either the phenotype of the CR-Fc binding cells (double
positive 5 cyan) or the proximity of these cells to other cell
types. 3D histograms were then created in order to accu-
rately assess the number and location of single or double
positive cells.
The coexpression of the murine DC-specific marker,
CD11c (using the N418 mab [17]), was assessed on lymph
node sections obtained before (day 0) and 1, 2, 3, and 4 d
after a primary immunization. In general, as shown in the
histograms of Fig. 1, CR-Fc binding cells represented a
subset of N4181 cells. Before antigenic stimulation (Fig. 1,
Day 0), no CR-Fc binding cells were observed below the
subcapsular sinus. Within 24 h of antigen injection (Fig. 1,
Day 1), CR-Fc single and CR-Fc/N418 double positive
cells appeared in the follicle. By day 2, the cells were scat-
tered throughout the follicle, becoming more organized
towards the edge of the follicle during days 3 and 4. At day
5, very few CR-Fc/N418 double positive cells were ob-
served except in the subcapsular sinus (data not shown).
As a control to address nonspecific Fc-mediated binding,
the sections (days 0–3) were incubated with human IgG in-
stead of the fusion protein CR-Fc. No binding was ob-
served on the tissue sections (data not shown). Finally, very
few, if any, N4181 interdigitating cells in the paracortex
demonstrated the ability to bind CR-Fc (Fig. 1).
Using this procedure, the expression of several proteins
was analyzed (Table I). The CR-Fc binding cells in the fol-
licles were observed to also express MHC class II and sial-
oadhesin, the latter being one of the ligands for CR-Fc
(Martinez-Pomares, L., and S. Gordon, manuscript in
preparation). A subset of cells expressed CD90 (Thy 1), es-
pecially the CR-Fc binding cells present at the border of
the B cell follicle and paracortex. At days 3 and 4, a minor
subset of cells also expressed CD8a and CD138 (Syndecan-
1). However, CD11b, Dec205, CD4, FDC-M2, F4/80,
and B220 were all absent. Taken together, these results re-855 Berney et al.
veal a novel pattern of protein expression for the CR-Fc
binding cells that localize in B cell follicles.
CR-Fc Binding Cells Associate with B and T Lymphocytes in
the Outer B Cell Follicles. Interestingly, many CR-Fc bind-
ing cells tended to localize at the border of the B cell folli-
cle (Fig. 1). As it had recently been reported that adoptively
transferred antigen-specific transgenic T and B cells colo-
calize in this region (11), we asked whether T cells could
be observed in the vicinity of CR-Fc binding cells. As
shown in Fig. 2 (see areas within boxes), indeed T cells
(CD41) were found to be mingled with B cells (IgM1) and
CR-Fc binding cells at the periphery of the follicle be-
tween days 3 and 4 after antigen injection.
CR-Fc Binding Cells Prime T Cells In Vivo. The kinet-
ics of their appearance in the particular anatomical location
and their expression of the murine DC-specific protein,
CD11c, suggested that CR-Fc binding cells play a role in
lymphocyte stimulation. To address this hypothesis, CR-Fc
Figure 2. B cells, T cells, and CR-Fc
binding cells colocalize in the outer B
cell follicles. Cryostat sections prepared
from murine lymph nodes obtained at
day 3 (A, C, and E) and day 4 (B, D,
and F) of a primary response were pro-
cessed for IgM expression (red), CD4 la-
beling (green), and CR-Fc binding
(blue). Especially at the higher magnifi-
cation (E and F) of the areas outlined in
C and D, CR-Fc binding cells (blue)
and T cells (green) can be observed
within the B cell follicles (red).856 CR-Fc Binding DCs Stimulate T and B Cell Responses
binding cells were isolated from draining lymph nodes 24 h
after subcutaneous injection of OVA and purified by flow
cytometry. As shown in Fig. 3, the CR-Fc binding cells
had a high side scatter value and were all CD11c1. Sorting
the CR-Fc binding cells using the R1 gate (Fig. 3) pro-
duced a purity of .99%.
The cells were then adoptively transferred into naive
mice, and 7 d later, the T cells were isolated separately
from the draining versus nondraining lymph nodes. As
shown in Fig. 4 A, the CR-Fc binding cells were able to
prime naive T cells, as no antigen-specific proliferation oc-
curred in T cells isolated from the nondraining side. These
results suggested that CR-Fc binding cells were capable of
antigen uptake in vivo followed by processing and presen-
tation of peptides to naive T cells.
CR-Fc Binding Cells Present Antigen to T Cells In Vitro.
To insure that CR-Fc binding cells could present antigen
they obtained in vivo, the cells, isolated in a similar manner
as above, were incubated in decreasing concentrations with
antigen-specific T cells. As few as 3,000 CR-Fc binding
cells (Fig. 4 B) were able to significantly stimulate the
DO11.10 transgenic T cells to proliferate in vitro. There-
fore, not only can CR-Fc binding cells take up antigen in
vivo, they can also act as antigen-presenting cells both in
vitro and in vivo.
CR-Fc Binding Cells Induce Antigen-specific Antibody Pro-
duction by B Cells. As B cells are stimulated to produce
the initial wave of antigen-specific Ig in the outer T cell
zones, an experiment was designed to ascertain if CR-Fc
binding cells played a role in this process. Similar to the
protocol mentioned above, CR-Fc binding cells were iso-
lated from draining lymph nodes 24 h after a subcutaneous
injection of OVA. In addition, CR-Fc nonbinding cells
were also obtained for comparison. The CR-Fc binding
cells were then adoptively transferred into the right fore-
limb of naive mice while the CR-Fc nonbinding cells
were injected into the left. 7 d later, the B cells were iso-
lated separately from the right versus left axillary and bra-
chial lymph nodes as well as the inguinal and paraaortic
lymph nodes (i.e., the sites receiving no cells). They were
then cultured for a further 7 d, at which time the superna-
tants were harvested. As shown in Fig. 5, only cells isolated
from lymph nodes receiving the CR-Fc binding cells pro-
duced antigen-specific antibody. Although only a remote
possibility due to the 24-h time point used for isolation,
contamination by preplasma cells in the CR-Fc prepara-
tions was ruled out by putting these cells in culture for 7 d
and assaying for antibody production by ELISA (none was
detected; data not shown). In addition, the same results as
shown in Fig. 5 were obtained when CR-Fc binding prep-
arations were subjected to a round of B220 depletion us-
ing magnetic beads before injection into mice (data not
shown).
Next, to determine the characteristics of the antigen-
specific antibody response in vivo after transfer of CR-Fc
Figure 3. Profile of CR-Fc binding cells by flow cytometry. 24 h after
a primary immunization, low buoyant density cells were labeled for CR-
Fc binding and N418 expression. Setting a gate (R1) using the scatter pa-
rameters demonstrated that all N4181 cells (gray) produced an elevated
side scatter pattern. The N418 single positive cells represented 50% of the
total low density population while 10% were N418/CR-Fc double posi-
tive.
Figure 4. T cell priming by CR-Fc binding cells. (A) CR-Fc binding cells were isolated from OVA-immune mice, then injected subcutaneously into
naive mice. 7 d later, the T cells were isolated from the lymph nodes on the side receiving the injection and compared with T cells isolated from non-
draining lymph nodes for in vitro restimulation. In the presence of splenic antigen-presenting cells, both T cell populations were incubated without (2)
or with (1) OVA. At 24 h, [3H]thymidine was added, and 24 h later, incorporation was assessed. (B) CR-Fc binding cells were isolated from immune
mice and then incubated at varying concentrations with 105 OVA-specific transgenic T cells. At 24 h, [3H]thymidine was added, and 24 h later, incorpo-
ration was assessed. Both sets of data are representative of three experiments.857 Berney et al.
binding cells, serum was collected from mice after a single
and second injection of cells. As shown in Fig. 6, a signifi-
cant increase was observed for OVA-specific IgG1 titers af-
ter both the primary and secondary injections. IgM did not
increase, although this was clearly observed when B cells
were assessed ex vivo (as in Fig. 5). These data suggest that
although the B cells that encounter CR-Fc cells can be-
come IgM-secreting cells ex vivo, left in vivo, they will en-
counter signals that drive IgG1 production and can be in-
duced to produce an increased level of antibody after a
secondary application of the stimulus. IgG2a and IgG2b an-
tigen-specific serum titers showed a slight but not statisti-
cally significant change. This observation suggests that
transfer of CR-Fc cells themselves does not promote the
development of microenvironments for downstream Ig
class switching events.
Cell Surface Molecules Expressed by Isolated CR-Fc Binding
DCs. Double immunolabeling in conjunction with flow
cytometry revealed that the CR-Fc binding cells were rich
in Fc (CD32) and complement (CD21/35) receptors (Fig.
7). In addition, they were positive for intercellular adhesion
molecule 1 (ICAM-1, CD54), CD40, and CD86 (B7-2)
whereas they expressed little to no CD80 (B7-1). The cells
also expressed sialoadhesin (Ser-4/3D6), one of the ligands
for CR-Fc. Finally, neither CD3 nor CD23 were ex-
pressed.
CR-Fc Binding Cells Differ from Interdigitating Cells and
Bone Marrow–derived DCs in Their Ability to Produce MIP-
1a. N4181/CR-Fc nonbinding cells (i.e., interdigitating
cells) and N4181/CR-Fc binding cells isolated 24 h after
antigen injection as well as N4181 DCs derived from bone
marrow (BM-DCs) were assessed for their capacity to
produce T cell chemoattractants. As shown in Fig. 8,
RANTES (for regulated upon activation, normal T cell ex-
pressed and secreted) production followed the hierarchy of
BM-DC , CR-Fc1/N4181  # CR-Fc2/N4181 (inter-
digitating cell). In contrast, only N4181/CR-Fc binding
cells produced MIP-1a.
Figure 5. OVA-specific antibody titers in B cell supernatants from the
lymph nodes of mice receiving CR-Fc binding versus nonbinding or no
cells. CR-Fc binding and nonbinding cells were isolated from OVA-
immune mice, then injected subcutaneously into naive mice. 7 d later, the
B cells were isolated from the lymph nodes on the side receiving CR-Fc
binding (black bars) or nonbinding (stippled bars) cells. In addition, B
cells from lymph nodes draining sites where no cells were injected were
also evaluated (white bars). The B cells were cultured for 7 d, and then
the supernatants were subjected to ELISA to determine the level of iso-
type-specific anti-OVA titers. The data are presented as the maximum di-
lution at which a titer was still observed. These data are representative of
five experiments.
Figure 6. OVA-specific serum titers of mice
receiving CR-Fc binding cells. CR-Fc binding
cells were isolated from OVA-immune mice,
then adoptively transferred subcutaneously into
naive mice (105 per mouse). 14 d later, the same
mice were injected subcutaneously a second
time with a freshly isolated preparation of CR-
Fc binding cells from OVA-immune mice (5 3
104 per mouse). Serum was obtained before the
primary (D0) and secondary (D14) injections.
Isotype-specific anti-OVA titers were assessed
by ELISA. Each data point represents the maxi-
mum dilution at which a titer was still observed
for an individual mouse.858 CR-Fc Binding DCs Stimulate T and B Cell Responses
Discussion
Using the CR-Fc binding property, we have identified a
population of cells that localize within B cell follicles.
These cells appear to be members of the DC family, as they
express CD11c in situ and ex vivo and are capable of prim-
ing naive T cells. Whether the cells belong to the myeloid
or lymphoid lineage is unclear, as CD11b and DEC205,
proteins normally associated with the myeloid and lym-
phoid DC lineage, respectively, were not detected. The
lack of F4/80, CD4, and FDC-M2 expression, molecules
found on macrophages (18), germinal center DCs (19), and
FDCs (20), respectively, further define these as a unique
DC subset.
As CR-Fc binding DCs appear mainly in the follicles
and not the paracortex, these cells may represent a popula-
tion specifically suited to precipitating the early phases of
humoral immunity. These cells provoke antigen-specific
antibody responses in vivo after adoptive transfer, and the
isotypes (i.e., IgM and IgG1) produced are restricted to that
associated with initial antibody responses (8, 9). These data
together with the in vitro and in vivo T cell priming results
are significant because they suggest that CR-Fc binding
cells have a mechanism not only for presenting peptide but
also for transporting native antigen to the B cell compart-
ment. Our observations concur with those of Wykes and
colleagues, who showed that DCs can capture and retain
unprocessed antigen in vitro and in vivo and could transfer
this antigen to naive B cells to initiate specific antibody re-
sponses (7). This mechanism would provide an efficient
means of initiating early protective immunity when physi-
ological (i.e., low) doses of virus or bacteria enter the body
and are encountered by the sentinel DCs. Indeed, low af-
finity polyclonal IgM is essential for the resistance of mice
to a systemic bacterial infection (21). Hence, DCs moving
in from the blood or interstitial sites, quickly providing
both peptide and native antigen for lymphocyte stimula-
tion in microenvironments of secondary lymphoid tissues,
would prove to be evolutionarily advantageous for survival.
The functional profile of these murine-derived CR-Fc
binding DCs parallels that of the human CD141-derived
DCs characterized by Caux and colleagues (22). The
CD141-derived DCs have a robust and long-lasting anti-
gen uptake capacity (22) resulting in the induction of effi-
cient T cell proliferation, and demonstrate a unique ability
to induce naive B cell differentiation into IgM-secreting
plasma cells. In addition, the accessory molecule profiles of
the murine and human DC subtypes are similar, as only
CD40 and CD86 are necessary for CD141-derived DC–
induced T cell proliferation while CD80 plays no role. As
shown in Fig. 7, the murine CR-Fc binding DC expresses
CD40 and CD86 but is negative for CD80.
Assessing the chemokine production by various murine
DC subsets demonstrated that CR-Fc binding DCs have a
unique phenotype compared with immature (day 6) BM-
DCs and interdigitating cells (the remaining population of
CD11c1 lymph node cells isolated 24 h after antigen injec-
Figure 7. Cell surface molecules expressed by isolated CR-Fc binding
cells. CR-Fc binding cells were isolated 24 h after OVA injection. The
cells were then double labeled for CR-Fc plus one of the markers indi-
cated. The fine line represents the level of fluorescence of CR-Fc binding
cells with a control antibody, and the bold line represents the level of ex-
pression on CR-Fc binding cells of the specific marker.
Figure 8. Chemokine production by the different subsets of DC. Day
6 BM-DCs, CR-Fc binding cells (CR-Fc1/N4181; isolated 24 h after
OVA injection), and interdigitating cells (CR-Fc2/N4181; isolated 24 h
after OVA injection) were isolated and cultured for 24 h in medium. Su-
pernatants were then harvested, and the levels of MIP-1a and RANTES
were determined by ELISA.859 Berney et al.
tion). Although the significance of a more robust MIP-1a
production remains to be shown, this may relate to the
CR-Fc binding DC ability to recruit cell types quickly into
the tissue (23). MIP-1a is reported to attract both T cells
and other DCs (24, 25). Furthermore, MIP-1a may also
act as a B cell chemoattractant, as B cells have been shown
to express mRNA for CC chemokine receptor CCR1 (26,
27). As other reagents become available to determine the
levels of murine chemokine production, we will be able to
further define the function of this cell type during immune
responses.
Is the CR-Fc binding DC a migratory cell, or are we
witnessing upregulation of a receptor on a resident popula-
tion? Based on the ability of the CR-Fc binding DCs to
prime naive T cells in lymph nodes after a subcutaneous
adoptive transfer as well as their similarity to human
CD141-derived DCs, we favor the former. The relation-
ship of the murine CR-Fc binding DC to the germinal
center DC remains to be further investigated. In the future,
the use of imaging systems as described by Robert and col-
leagues (28) should provide the means to trace the exact
fate of CR-Fc binding cells in vivo.
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